Search for content, post, videos

LIDDS to apply for listing on Nasdaq Stockholm Main Market

Monica Wallter

A listing on Nasdaq Stockholm Main Market is a natural next step in the company’s development, it states.

“A move to Nasdaq Stockholm’s main market can contribute to increased interest from a broader investor base while at the same time increase the visibility and exposure of LIDDS, in Sweden and globally,” says Monica Wallter, CEO, LIDDS.

“We now have larger and longer-term institutional and private investors”

LIDDS is in a strong growth and expansion phase with several key projects in clinical and preclinical phases, including Phase III Liproca Depot out-licensing, the Phase I NanoZolid-docetaxel study and an extensive preclinical program in immuno-oncology, it states.

“It is clear that our shareholder base has developed significantly in recent years, both in terms of number of shareholders and that we now have larger and longer-term institutional and private investors,” says Jan Törnell, Chairman of the Board of LIDDS.

A transition from Nasdaq First North to Nasdaq Stockholm’s Main Market has the potential to increase LIDDS visibility both locally and internationally, it states.

Photo of Monica Wallter: LIDDS